In a phase I/II clinical trial in the recruiting phase, patients with newly diagnosed, high-risk prostate cancer will receive a DNA vaccine encoding the ligand-binding domain of the androgen receptor (pTVG-AR) combined with androgen deprivation therapy with Degarelix (a GnRH-receptor antagonist injected subcutaneously) and nivolumab/cemiplimab/fianlimab. The gene discussed is AR; the disease is prostate carcinoma.